84 related articles for article (PubMed ID: 3890700)
1. Mesulergine (CU32-085) in the treatment of Parkinson's disease.
Pfeiffer RF; Wilken K; Glaeske C
Ann Neurol; 1985 Apr; 17(4):334-6. PubMed ID: 3890700
[TBL] [Abstract][Full Text] [Related]
2. CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's disease.
Rascol O; Fabre N; Teräväinen H; Poewe W; Lücking C; Rinne U; Dupont E; Hirt D; Hoyer M; Lataste X
Clin Neuropharmacol; 1990 Aug; 13(4):303-11. PubMed ID: 2208182
[TBL] [Abstract][Full Text] [Related]
3. Mesulergine in early Parkinson's disease: a double blind controlled trial.
Dupont E; Mikkelsen B; Jakobsen J
J Neurol Neurosurg Psychiatry; 1986 Apr; 49(4):390-5. PubMed ID: 3517235
[TBL] [Abstract][Full Text] [Related]
4. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
[TBL] [Abstract][Full Text] [Related]
5. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
Metman LV; Blanchet PJ; de Jong D; Mouradian MM; Chase TN
Mov Disord; 1996 May; 11(3):257-60. PubMed ID: 8723141
[TBL] [Abstract][Full Text] [Related]
6. Placebo-controlled study of mesulergine in Parkinson's disease.
Jankovic J; Orman J; Jansson B
Neurology; 1985 Feb; 35(2):161-5. PubMed ID: 3881692
[TBL] [Abstract][Full Text] [Related]
7. Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage.
Giménez-Roldán S; Tolosa E; Burguera JA; Chacón J; Liaño H; Forcadell F
Clin Neuropharmacol; 1997 Feb; 20(1):67-76. PubMed ID: 9037575
[TBL] [Abstract][Full Text] [Related]
8. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of pergolide and mesulergine.
Lieberman AN; Gopinathan G; Neophytides A
Eur Neurol; 1986; 25(2):86-90. PubMed ID: 3948891
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Parkinson's disease with the ergoline derivatives CQ 32-084 and CU 32-085.
Pakkenberg H; Jensen I
Adv Neurol; 1983; 37():151-7. PubMed ID: 6344587
[TBL] [Abstract][Full Text] [Related]
11. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease.
Nausieda PA; Pfeiffer RF; Tagliati M; Kastenholz KV; DeRoche C; Slevin JT
Clin Ther; 2005 Jan; 27(1):58-63. PubMed ID: 15763606
[TBL] [Abstract][Full Text] [Related]
12. A double-blind evaluation of ciladopa in Parkinson's disease.
Weiner WJ; Factor SA; Sanchez-Ramos J; Berger J
Mov Disord; 1987; 2(3):211-7. PubMed ID: 3332914
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic results with a new ergoline derivate (8-alpha-amino-ergoline, CU 32-085) in parkinsonian patients.
Schneider E; Hubener K; Fischer PA
Adv Neurol; 1984; 40():527-9. PubMed ID: 6695631
[No Abstract] [Full Text] [Related]
14. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
Im JH; Ha JH; Cho IS; Lee MC
J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999
[TBL] [Abstract][Full Text] [Related]
15. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up.
Rodriguez-Oroz MC; Obeso JA; Lang AE; Houeto JL; Pollak P; Rehncrona S; Kulisevsky J; Albanese A; Volkmann J; Hariz MI; Quinn NP; Speelman JD; Guridi J; Zamarbide I; Gironell A; Molet J; Pascual-Sedano B; Pidoux B; Bonnet AM; Agid Y; Xie J; Benabid AL; Lozano AM; Saint-Cyr J; Romito L; Contarino MF; Scerrati M; Fraix V; Van Blercom N
Brain; 2005 Oct; 128(Pt 10):2240-9. PubMed ID: 15975946
[TBL] [Abstract][Full Text] [Related]
16. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa.
Metman LV; Hoff J; Mouradian MM; Chase TN
Mov Disord; 1994 Jul; 9(4):463-5. PubMed ID: 7969216
[TBL] [Abstract][Full Text] [Related]
17. Pergolide and lisuride in advanced Parkinson's disease.
Lieberman AN; Gopinathan G; Neophytides A; Leibowitz M; Goldstein M
Adv Neurol; 1984; 40():503-7. PubMed ID: 6695627
[TBL] [Abstract][Full Text] [Related]
18. Mesulergine (CU 32-085) in the treatment of Parkinson's disease.
Rascol A; Montastruc JL; Rascol O; Senard JM
Clin Neuropharmacol; 1986; 9(2):146-52. PubMed ID: 3708600
[TBL] [Abstract][Full Text] [Related]
19. [Clozapine in the treatment of adverse psychiatric manifestations of long-term therapy with levodopa].
Svetel MV; Sternić NM; Filipović SR; Vojvodić NM; Kostić VS
Srp Arh Celok Lek; 1997; 125(7-8):203-6. PubMed ID: 9304232
[TBL] [Abstract][Full Text] [Related]
20. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group.
Rascol O; Brooks DJ; Brunt ER; Korczyn AD; Poewe WH; Stocchi F
Mov Disord; 1998 Jan; 13(1):39-45. PubMed ID: 9452324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
